The AACR Annual Meeting 2023 set a new record this year with the number of clinical trial abstracts submitted to the meeting. More than 240 abstracts were showcased over the course of the meeting...
Earlier this month, over 21,000 researchers, clinicians, patients, and other stakeholders gathered at the AACR Annual Meeting 2023 to discuss the latest advances across the continuum of cancer research—from basic science to clinical research...
Historically, most cancer drugs have been tested separately in adults and children. For the approval of new drugs for children, researchers must ensure that doses are properly recalculated and new side effects do not...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in the plenary hall and virtually to watch the Opening Plenary Session of the AACR Annual...
People of African descent who receive genetic testing have fewer actionable mutations compared with white people—suggesting fewer available treatment options.
New study finds drug combination after surgery helps prevent recurrence in liver cancer patients.
The 2015 approval of an immune checkpoint inhibitor for renal cell carcinoma (RCC) provided a much-needed new treatment option for patients with this disease, which causes almost 14,000 deaths each year, the majority of...
Accumulating research shows lifelong stressors degrade health and increase cancer risk, but exercise might help counteract the impact of stress.
Study finds mRNA vaccine can help prevent cancer recurrence in advanced melanoma patients.
The plenary program of the AACR Annual Meeting 2023 kicked off Saturday, April 15, with a session titled “Beating KRAS: A 30-year Overnight Sensation.” The plenary session was chaired by Dafna Bar-Sagi, PhD, FAACR,...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More